array:19 [
  "pii" => "X0211699504029688"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2004-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2004;24 Supl 1:27"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2029
    "formatos" => array:3 [
      "EPUB" => 225
      "HTML" => 1376
      "PDF" => 428
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X021169950402967X"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:28"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2123
      "formatos" => array:3 [
        "EPUB" => 257
        "HTML" => 1444
        "PDF" => 422
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Progresión del sistema renina angiotensina, remisión y regresión de las nefropatías crónicas"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "28"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "G. REMUZZI"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "G. REMUZZI"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X021169950402967X?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X021169950402967X/v0_201502091335/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699504029696"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:26"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2629
      "formatos" => array:3 [
        "EPUB" => 248
        "HTML" => 1928
        "PDF" => 453
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Angiotensina II: auténtica citoquina en el daño vascular"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "26"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. EGIDO , M. RUIZ-ORTEGA , V. ESTEBAN , M. RUPEREZ , E. SANCHEZ LOPEZ , A. F. LOPEZ , J. RODRIGUEZ VITA"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. EGIDO , M. RUIZ-ORTEGA , V. ESTEBAN , M. RUPEREZ , E. SANCHEZ LOPEZ , A. F. LOPEZ , J. RODRIGUEZ VITA"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029696?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029696/v0_201502091335/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Efecto del bloqueo del sistema renina angiotensina sobre la progresión de la nefropatía diabética"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "27"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "S. SHAHINFAR"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "S. SHAHINFAR"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XXIV. Número Extraordinario (I). 2004 Efecto del bloqueo del sistema renina angiotensina sobre la progresión de la nefropatía diabética S. Shahinfar, M.D. Pennsylvania. USA. Diabetes mellitus is one of the most common diseases worldwide. It has been estimated that the total number of diabetic patients worldwide will increase from 123 million (1997) to 220 million by the Year 2010, with approximately 97% of all diabetics being type 2. Up to 40% of type 2 diabetics develop kidney disease, and in certain geographical regions, approximately 40% of new patients receiving renal replacement therapy have diabetic nephropathy. In the United States, the overall incidence of ESRD continues to increase, while the number of new ESRD cases attributed to diabetes is projected to rise sevenfold by 2030. Both hemodynamic and non-hemodynamic mechanisms may contribute to the progression of diabetic nephropathy. Since angiotensin II (AII) plays a central role in these mechanisms, it therefore has been hypothesized that blockade of AII would be renal protective in patients with type 2 diabetes. In experimental models of both non-diabetic and diabetic renal disease, AII receptor antagonism with losartan has been shown to reduce intraglomerular pressure and glomerular sclerosis, and reduce urinary protein excretion. These findings were supported in non-diabetic patients where losartan lowered blood pressure, decreased urinary protein excretion, and elevated renal plasma flow. In type 1 diabetes, ACE inhibition was demonstrated to slow the progression of renal disease, however there was no definitive evidence of a benefit on ESRD in type 2 diabetes. The RENAAL study was initiated to investigate the long-term renal protective effects of losartan in pa- tients with type 2 diabetes and nephropathy. The study demonstrated that losartan compared to placebo (with or without conventional antihypertensive therapy) significantly reduced the incidence of and delayed the time to the composite outcome of doubling of serum creatinine, ESRD, or death. RENAAL also demonstrated for the first time that blockade of angiotensin II with losartan delayed ESRD and the composite endpoint of ESRD or death. Losartan compared to placebo also significantly reduced proteinuria over time. The RENAAL study also revealed the association between important risk factors and renal outcomes in this type 2 diabetic population with nephropathy. Baseline metabolic factors were shown to be associated with the composite endpoint as well as ESRD, while anemia was shown to be an independent risk factor for rate of glomerular filtration rate decline and ESRD. Baseline proteinuria also was shown to be an important predictor for renal outcomes in this population. Furthermore, from RENAAL we have learned that imbalances in distribution of baseline proteinuria between treatment groups may affect treatment outcomes in studies of renal diseases. In summary, the results from the RENAAL study have fulfilled an unmet medical need by providing evidence that AII receptor antagonism is effective in delaying the onset of ESRD in type 2 diabetes, and well-tolerated in this vulnerable population. This study also revealed important information on the predictive nature of certain risk factors for renal outcome in type 2 diabetic patients with nephropathy. 27 "
    "pdfFichero" => "P7-E232-S132-A2977.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029688/v0_201502091335/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35393"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Artículos Originales"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000024000000S1/v0_201502091335/X0211699504029688/v0_201502091335/en/P7-E232-S132-A2977.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029688?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Efecto del bloqueo del sistema renina angiotensina sobre la progresión de la nefropatía diabética
S. SHAHINFAR
Leído
4995
Veces
se ha leído el artículo
1897
Total PDF
3098
Total HTML
Compartir estadísticas
 array:19 [
  "pii" => "X0211699504029688"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2004-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2004;24 Supl 1:27"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2029
    "formatos" => array:3 [
      "EPUB" => 225
      "HTML" => 1376
      "PDF" => 428
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X021169950402967X"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:28"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2123
      "formatos" => array:3 [
        "EPUB" => 257
        "HTML" => 1444
        "PDF" => 422
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Progresión del sistema renina angiotensina, remisión y regresión de las nefropatías crónicas"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "28"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "G. REMUZZI"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "G. REMUZZI"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X021169950402967X?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X021169950402967X/v0_201502091335/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699504029696"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:26"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2629
      "formatos" => array:3 [
        "EPUB" => 248
        "HTML" => 1928
        "PDF" => 453
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Angiotensina II: auténtica citoquina en el daño vascular"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "26"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. EGIDO , M. RUIZ-ORTEGA , V. ESTEBAN , M. RUPEREZ , E. SANCHEZ LOPEZ , A. F. LOPEZ , J. RODRIGUEZ VITA"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. EGIDO , M. RUIZ-ORTEGA , V. ESTEBAN , M. RUPEREZ , E. SANCHEZ LOPEZ , A. F. LOPEZ , J. RODRIGUEZ VITA"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029696?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029696/v0_201502091335/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Efecto del bloqueo del sistema renina angiotensina sobre la progresión de la nefropatía diabética"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "27"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "S. SHAHINFAR"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "S. SHAHINFAR"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XXIV. Número Extraordinario (I). 2004 Efecto del bloqueo del sistema renina angiotensina sobre la progresión de la nefropatía diabética S. Shahinfar, M.D. Pennsylvania. USA. Diabetes mellitus is one of the most common diseases worldwide. It has been estimated that the total number of diabetic patients worldwide will increase from 123 million (1997) to 220 million by the Year 2010, with approximately 97% of all diabetics being type 2. Up to 40% of type 2 diabetics develop kidney disease, and in certain geographical regions, approximately 40% of new patients receiving renal replacement therapy have diabetic nephropathy. In the United States, the overall incidence of ESRD continues to increase, while the number of new ESRD cases attributed to diabetes is projected to rise sevenfold by 2030. Both hemodynamic and non-hemodynamic mechanisms may contribute to the progression of diabetic nephropathy. Since angiotensin II (AII) plays a central role in these mechanisms, it therefore has been hypothesized that blockade of AII would be renal protective in patients with type 2 diabetes. In experimental models of both non-diabetic and diabetic renal disease, AII receptor antagonism with losartan has been shown to reduce intraglomerular pressure and glomerular sclerosis, and reduce urinary protein excretion. These findings were supported in non-diabetic patients where losartan lowered blood pressure, decreased urinary protein excretion, and elevated renal plasma flow. In type 1 diabetes, ACE inhibition was demonstrated to slow the progression of renal disease, however there was no definitive evidence of a benefit on ESRD in type 2 diabetes. The RENAAL study was initiated to investigate the long-term renal protective effects of losartan in pa- tients with type 2 diabetes and nephropathy. The study demonstrated that losartan compared to placebo (with or without conventional antihypertensive therapy) significantly reduced the incidence of and delayed the time to the composite outcome of doubling of serum creatinine, ESRD, or death. RENAAL also demonstrated for the first time that blockade of angiotensin II with losartan delayed ESRD and the composite endpoint of ESRD or death. Losartan compared to placebo also significantly reduced proteinuria over time. The RENAAL study also revealed the association between important risk factors and renal outcomes in this type 2 diabetic population with nephropathy. Baseline metabolic factors were shown to be associated with the composite endpoint as well as ESRD, while anemia was shown to be an independent risk factor for rate of glomerular filtration rate decline and ESRD. Baseline proteinuria also was shown to be an important predictor for renal outcomes in this population. Furthermore, from RENAAL we have learned that imbalances in distribution of baseline proteinuria between treatment groups may affect treatment outcomes in studies of renal diseases. In summary, the results from the RENAAL study have fulfilled an unmet medical need by providing evidence that AII receptor antagonism is effective in delaying the onset of ESRD in type 2 diabetes, and well-tolerated in this vulnerable population. This study also revealed important information on the predictive nature of certain risk factors for renal outcome in type 2 diabetic patients with nephropathy. 27 "
    "pdfFichero" => "P7-E232-S132-A2977.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029688/v0_201502091335/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35393"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Artículos Originales"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000024000000S1/v0_201502091335/X0211699504029688/v0_201502091335/en/P7-E232-S132-A2977.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029688?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 3 11 14
2024 Octubre 40 27 67
2024 Septiembre 40 30 70
2024 Agosto 55 48 103
2024 Julio 36 21 57
2024 Junio 50 36 86
2024 Mayo 48 25 73
2024 Abril 38 26 64
2024 Marzo 28 23 51
2024 Febrero 28 34 62
2024 Enero 28 22 50
2023 Diciembre 24 20 44
2023 Noviembre 34 22 56
2023 Octubre 21 24 45
2023 Septiembre 24 31 55
2023 Agosto 38 25 63
2023 Julio 28 20 48
2023 Junio 32 14 46
2023 Mayo 35 29 64
2023 Abril 23 16 39
2023 Marzo 18 21 39
2023 Febrero 28 22 50
2023 Enero 36 27 63
2022 Diciembre 39 33 72
2022 Noviembre 38 27 65
2022 Octubre 34 46 80
2022 Septiembre 28 25 53
2022 Agosto 35 34 69
2022 Julio 31 59 90
2022 Junio 23 32 55
2022 Mayo 31 33 64
2022 Abril 35 45 80
2022 Marzo 40 32 72
2022 Febrero 35 28 63
2022 Enero 26 33 59
2021 Diciembre 45 33 78
2021 Noviembre 29 38 67
2021 Octubre 25 34 59
2021 Septiembre 30 38 68
2021 Agosto 20 36 56
2021 Julio 26 23 49
2021 Junio 17 13 30
2021 Mayo 24 36 60
2021 Abril 65 50 115
2021 Marzo 30 28 58
2021 Febrero 36 14 50
2021 Enero 18 12 30
2020 Diciembre 16 14 30
2020 Noviembre 18 3 21
2020 Octubre 11 13 24
2020 Septiembre 7 6 13
2020 Agosto 26 6 32
2020 Julio 34 11 45
2020 Junio 15 11 26
2020 Mayo 35 17 52
2020 Abril 32 16 48
2020 Marzo 17 11 28
2020 Febrero 30 18 48
2020 Enero 29 22 51
2019 Diciembre 21 14 35
2019 Noviembre 26 16 42
2019 Octubre 14 7 21
2019 Septiembre 21 16 37
2019 Agosto 3 10 13
2019 Julio 21 23 44
2019 Junio 18 15 33
2019 Mayo 15 23 38
2019 Abril 38 27 65
2019 Marzo 12 15 27
2019 Febrero 12 10 22
2019 Enero 12 13 25
2018 Diciembre 34 25 59
2018 Noviembre 45 9 54
2018 Octubre 44 14 58
2018 Septiembre 26 10 36
2018 Agosto 17 8 25
2018 Julio 17 11 28
2018 Junio 13 8 21
2018 Mayo 23 12 35
2018 Abril 16 8 24
2018 Marzo 17 7 24
2018 Febrero 17 5 22
2018 Enero 17 5 22
2017 Diciembre 19 4 23
2017 Noviembre 14 6 20
2017 Octubre 17 4 21
2017 Septiembre 9 8 17
2017 Agosto 11 5 16
2017 Julio 12 5 17
2017 Junio 12 6 18
2017 Mayo 15 4 19
2017 Abril 21 6 27
2017 Marzo 12 3 15
2017 Febrero 13 5 18
2017 Enero 9 10 19
2016 Diciembre 9 5 14
2016 Noviembre 10 3 13
2016 Octubre 14 5 19
2016 Septiembre 26 2 28
2016 Agosto 41 0 41
2016 Julio 52 1 53
2016 Junio 50 0 50
2016 Mayo 51 0 51
2016 Abril 32 0 32
2016 Marzo 28 0 28
2016 Febrero 39 0 39
2016 Enero 38 0 38
2015 Diciembre 51 0 51
2015 Noviembre 46 0 46
2015 Octubre 39 0 39
2015 Septiembre 27 0 27
2015 Agosto 52 0 52
2015 Julio 21 0 21
2015 Junio 22 0 22
2015 Mayo 16 0 16
2015 Abril 6 0 6
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?